Payment overview · 2025
General Payments
$361.96
15 reported records · 5 companies
Healthcare provider profile · identity verified
Michele A Candelore, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · FORT MYERS, FL · NPI 1720146566
Verified facts
What the public records show
CMS Open Payments records show Michele A Candelore, D.O. received $361.96 in general payments during 2025 across 15 reported records.
Amgen Inc. accounted for 78.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $285.37 | 78.8% | 11 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $22.35 | 6.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.76 | 5.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.13 | 4.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.35 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $361.96 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $208.45 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $80.95 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $76.92 | 4 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $23.30 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $22.35 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
120 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
107 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
29 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 605 | 178 |
| Atorvastatin Calcium | Atorvastatin Calcium | 455 | 154 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 421 | 139 |
| Lisinopril | Lisinopril | 383 | 124 |
| Amlodipine Besylate | Amlodipine Besylate | 369 | 118 |
| Montelukast Sodium | Montelukast Sodium | 324 | 129 |
| Losartan Potassium | Losartan Potassium | 247 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 247 | 79 |
| Alprazolam | Alprazolam | 223 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 211 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 210 | 74 |
| Omeprazole | Omeprazole | 181 | 68 |
| Gabapentin | Gabapentin | 169 | 52 |
| Metformin Hcl | Metformin Hcl | 158 | 52 |
| Trazodone Hcl | Trazodone Hcl | 153 | 54 |
| Simvastatin | Simvastatin | 143 | 44 |
| Meloxicam | Meloxicam | 136 | 46 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 132 | 45 |
| Glimepiride | Glimepiride | 127 | 37 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 125 | 41 |
| Furosemide | Furosemide | 124 | 43 |
| Ozempic | Semaglutide | 120 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 119 | 42 |
| Ezetimibe | Ezetimibe | 118 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 116 | 36 |
| Carvedilol | Carvedilol | 112 | 35 |
| Sertraline Hcl | Sertraline Hcl | 112 | 39 |
| Bupropion Xl | Bupropion Hcl | 109 | 39 |
| Eliquis | Apixaban | 107 | 31 |
| Atenolol | Atenolol | 98 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 92 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 32 |
| Famotidine | Famotidine | 85 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | 27 |
| Fenofibrate | Fenofibrate | 75 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 23 |
| Potassium Chloride | Potassium Chloride | 69 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 30 |
| Pregabalin | Pregabalin | 67 | 29 |
| Synthroid | Levothyroxine Sodium | 67 | 20 |
| Allopurinol | Allopurinol | 66 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 65 | 19 |
| Methylprednisolone | Methylprednisolone | 63 | 54 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 62 | 23 |
| Januvia | Sitagliptin Phosphate | 62 | 17 |
| Jardiance | Empagliflozin | 59 | 20 |
| Cefdinir | Cefdinir | 56 | 53 |
| Estradiol | Estradiol | 53 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 19 |
| Mounjaro | Tirzepatide | 48 | 11 |
| Valacyclovir | Valacyclovir Hcl | 48 | 25 |
| Diazepam | Diazepam | 46 | 14 |
| Prednisone | Prednisone | 46 | 30 |
| Propranolol Hcl | Propranolol Hcl | 46 | 14 |
| Torsemide | Torsemide | 46 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 14 |
| Rybelsus | Semaglutide | 43 | 11 |
| Clonazepam | Clonazepam | 41 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 40 | 11 |
| Lovastatin | Lovastatin | 38 | 11 |
| Ondansetron Odt | Ondansetron | 38 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 38 | 11 |
| Topiramate | Topiramate | 37 | 16 |
| Baclofen | Baclofen | 36 | 14 |
| Celecoxib | Celecoxib | 36 | 18 |
| Azithromycin | Azithromycin | 35 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | 14 |
| Gemtesa | Vibegron | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Lorazepam | Lorazepam | 33 | 15 |
| Repatha Sureclick | Evolocumab | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 30 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | 11 |
| Xarelto | Rivaroxaban | 32 | 13 |
| Ibandronate Sodium | Ibandronate Sodium | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | 12 |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 29 | 11 |
| Nitroglycerin | Nitroglycerin | 29 | 16 |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 29 |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Finasteride | Finasteride | 28 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 28 | suppressed |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 14 |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Nystatin | Nystatin | 25 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 14 |
| Olanzapine | Olanzapine | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Jantoven | Warfarin Sodium | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Telmisartan | Telmisartan | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 11 |
| Sucralfate | Sucralfate | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Progesterone | Progesterone, Micronized | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $361.96 · 15 records | Amgen Inc. | ABRYSVO, CAPVAXIVE, COMIRNATY, EVENITY, LEQVIO, OTEZLA, PREVNAR 20, PROLIA, REPATHA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error